FDA Peptide Reclassification 2026: What Researchers Need to Know
Key Takeaways
- HHS Secretary Kennedy directed the FDA to reclassify 12 peptides from Category 2 to Category 1
- This reverses the September 2023 restrictions on compounding
- Reclassification allows compounding under physician prescription — it is not FDA approval
- PCAC advisory meetings are scheduled beginning July 2026
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly stated his intention to reverse the 2023 FDA decision that moved 19 widely-used peptides to the Category 2 restricted list — effectively banning compounding pharmacies from producing them. By April 15, 2026, Kennedy formally directed the FDA to begin the reclassification process for 12 of those peptides.
Background: The 2023 Restrictions
In September 2023, the FDA identified 19 peptide compounds as presenting potential safety risks and placed them on the Category 2 bulk drug substances list under Section 503A. This prohibited licensed compounding pharmacies from preparing these peptides, even under valid physician prescriptions.
The decision was immediately controversial. Many clinicians, compounding pharmacy associations, and researchers argued that the FDA lacked specific safety signals to justify the broad restriction. Several of the affected peptides had decades of published research and established safety profiles.
Peptides Under Review
| Peptide | Primary Research Focus | Notes |
|---|---|---|
| BPC-157 | Tissue repair, gut healing | 100+ published studies |
| TB-500 | Muscle/tissue repair, wound healing | Thymosin Beta-4 fragment |
| Thymosin Alpha-1 | Immune modulation | Infectious disease, oncology support |
| CJC-1295 | Growth hormone release | Sleep, metabolism, lean muscle |
| Ipamorelin | Growth hormone release | Often paired with CJC-1295 |
| AOD-9604 | Fat metabolism | GH peptide fragment |
| Semax | Cognitive function | Rx-approved in Russia |
| Selank | Anxiety, immune modulation | Rx-approved in Russia |
| KPV | Intestinal inflammation | Alpha-MSH tripeptide |
| MOTS-C | Metabolic regulation, obesity | Mitochondrial-derived |
| GHK-Cu | Tissue remodeling, anti-aging | 162+ PubMed citations, highest safety grade |
| DSIP | Sleep regulation | Delta sleep-inducing peptide |
What Reclassification Means
Category 1
May Be Compounded
Sufficient safety data for continued evaluation. Licensed 503A pharmacies can compound under physician prescription.
Category 2
Cannot Be Compounded
Significant safety risks identified. Requires formal FDA rulemaking to authorize compounding.
Category 3
Insufficient Data
Lacks documentation for FDA evaluation. Cannot be compounded as active ingredients.
Important: Moving from Category 2 → Category 1 restores compounding eligibility. It does not constitute FDA approval, which requires clinical trials, safety/efficacy review, and an NDA or BLA.
The Gray Market Problem
One of the strongest arguments for reversing the restrictions has been the unintended consequence of driving consumers to unregulated sources. The Category 2 restrictions effectively created a gray market, with products carrying significant risks: contamination, incorrect dosing, mislabeling, and zero quality control.
Restoring regulated access through licensed pharmacies with established quality standards represents a fundamentally safer framework.
Timeline
Neogenesis BioLabs will continue to provide updates as the regulatory process unfolds.
Sources
- U.S. Federal Register — Pharmacy Compounding Advisory Committee; Notice of Meeting, Document No. 2026-07361. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- U.S. Food & Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503A. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a
- The Hill — FDA to weigh lifting restrictions on some MAHA-favored peptides, April 15, 2026. https://thehill.com/policy/healthcare/5832457-fda-considers-peptide-access/
- BioPharma Dive — FDA moves toward easing restrictions on certain peptides, April 16, 2026. https://www.biopharmadive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817685/
- Healthcare Dive — FDA moves toward easing restrictions on certain peptides, April 16, 2026. https://www.healthcaredive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817707/
Last updated: April 17, 2026